Washington Research Foundation and Arch Venture Partners are among the investors in the genomic cancer treatment spinout of University of Minnesota.
ApoGen Biotechnologies, a cancer therapy developer spun out of University of Minnesota, has secured $7m in a series A round featuring Arch Venture Partners, the VC firm spun out of Chicago University.
WRF Capital, the investment arm of Washington Research Foundation, a commercialisation firm focused on Washington state, also participated, as did biotech investment firm Accelerator Corporation, itself also backed by WRF.
Other investors include pharmaceutical firms AbbVie, Eli Lilly, WuXi PharmaTech and Johnson & Johnson, as well as…
